Satellos Bioscience Inc. (MSLE)
| Market Cap | 138.49M +41.1% |
| Revenue (ttm) | n/a |
| Net Income | -34.61M |
| EPS | -2.02 |
| Shares Out | 21.22M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,722 |
| Open | 6.53 |
| Previous Close | 6.63 |
| Day's Range | 6.42 - 6.73 |
| 52-Week Range | 5.30 - 13.40 |
| Beta | 1.15 |
| Analysts | Strong Buy |
| Price Target | 24.17 (+276.48%) |
| Est. Earnings | Nov 15, 2026 |
About MSLE
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for MSLE stock is "Strong Buy." The 12-month stock price target is $24.17, which is an increase of 276.48% from the latest price.
News
Satellos to Participate in Upcoming Investor Conferences
TORONTO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage company developing potentially life-improving medicines to treat degenerative muscle dis...
Craig-Hallum initiates Satellos with a Buy ahead of BASECAMP data
As previously reported, Craig-Hallum initiated coverage of Satellos (MSLE) with a Buy rating and $24 price target The firm likes the setup ahead of Q1 2027 BASECAMP data, with shares…
Satellos initiated with a Buy at Craig-Hallum
Craig-Hallum initiated coverage of Satellos (MSLE) with a Buy rating and $24 price target
Satellos granted composition of matter patent for forazapadin
Satellos (MSLE) announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,747,245, entitled “AP2 associated kinase 1 inhibitors and uses thereof.” The patent includes ...
Satellos Granted Composition of Matter Patent for Forazapadin
Composition of matter provides U.S. protection through Sept. 6, 2044, as forazapadin advances in Phase 2 development TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — Satellos Bioscience Inc. (NASDAQ: MSLE, T...
Satellos Granted Composition of Matter Patent for Forazapadin
Composition of matter provides U.S. protection through Sept. 6, 2044, as forazapadin advances in Phase 2 development Composition of matter provides U.S. protection through Sept. 6, 2044, as forazapadi...
Satellos Completes Enrollment In Phase 2 Forazapadin Trial For DMD
(RTTNews) - On Wednesday, Satellos Bioscience (MSLE) said it has completed enrollment in BASECAMP, a Phase 2 clinical trial evaluating forazapadin for the treatment of Duchenne muscular dystrophy (DMD...
Satellos announces enrollment completed for BASECAMP
Satellos (MSLE) Bioscience announced that enrollment has been completed for BASECAMP, the company’s Phase 2 clinical trial evaluating forazapadin for the treatment of Duchenne muscular dystrophy, DMD,...
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
Data from BASECAMP expected in Q1 2027 TORONTO, Sept. 30, 2026 (GLOBE NEWSWIRE) — Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improvin...
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
TORONTO, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative musc...
Satellos Bioscience (MSLE) Gains FDA IND Approval, Eyes Phase 2 Trial for FSHD
Satellos Bioscience (MSLE) Gains FDA IND Approval, Eyes Phase 2 Trial for FSHD
Satellos Gets FDA Clearance For Forazapadin In FSHD; Phase 2 Study Planned
(RTTNews) - Satellos Bioscience Inc. (MSLE) announced that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug application for forazapadin for the treatment of facioscapul...
Satellos announces U.S. FDA cleared IND application for forazapadin
Satellos (MSLE) Bioscience announced that the U.S. Food and Drug Administration, FDA, has cleared its Investigational New Drug, IND, application for forazapadin for the treatment of facioscapulohumera...
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing potentially life-improving medicines to treat degen...
Satellos Bioscience Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Forazapadin offers a novel, non-genetic approach to DMD by targeting muscle stem cell regeneration, with promising early clinical results and ongoing trials in both adults and children. The company is preparing for regulatory discussions and expanding into FSHD, supported by strong financials.
Satellos to Present at the 31st Annual Congress of the World Muscle Society
TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative musc...
Satellos Bioscience Slides: Corporate presentation
Satellos Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on September 10, 2026.
Satellos Bioscience Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The conference highlighted forazapadin's novel approach to muscle regeneration in Duchenne and FSHD, with two phase II trials set to deliver key data by early next year. Early results show functional and biomarker improvements, and expansion into FSHD is planned.
Satellos Bioscience (MSLE) Gains INN for Forazapadin Amid Unprofitable Status and Mixed Market ...
Satellos Bioscience (MSLE) Gains INN for Forazapadin Amid Unprofitable Status and Mixed Market Signals
Satellos Names Forazapadin As INN For Lead DMD Drug Candidate
(RTTNews) - Satellos Bioscience Inc. (MSLE) announced that the World Health Organization has assigned the International Nonproprietary Name (INN) forazapadin to its lead drug candidate, previously kno...
Satellos assigns forazapadin name to SAT-3247
Satellos (MSLE) announced the assignment of the International Nonproprietary Name, or INN, “forazapadin” for the company’s orally administered, small molecule drug candidate designed to restore muscle...
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) — Satellos Bioscience (Nasdaq: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle dis...
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience (Nasdaq: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle di...
Satellos to Participate in Upcoming Investor Conferences
Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced that management...
Satellos to Participate in Upcoming Investor Conferences
TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative musc...